Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levonorgestrel - Bayer Healthcare Pharmaceuticals

Next Previous
Drug Profile

Levonorgestrel - Bayer Healthcare Pharmaceuticals

Alternative Names: BAY 865028; Levonorgestrel IUS; Levonova; LNG IUS; LNG-IUS - Bayer; Menopausal levonorgestrel system; Mirena; MLS

Latest Information Update: 09 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering Oy
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Hormonal contraceptives; Hormonal replacements; Norpregnanes; Progesterone congeners; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Menorrhagia; Pregnancy; Uterine diseases
  • Phase III Endometrial hyperplasia
  • No development reported Menopausal syndrome

Most Recent Events

  • 24 Nov 2025 Phase-III clinical trials in Endometrial hyperplasia in USA (Intrauterine) (NCT06904274)
  • 08 Apr 2025 Bayer plans the phase III SUNFLOWER trial for Endometrial hyperplasia (In adolescents, In adults, In the elderly) in USA, China (Intrauterine), in June 2025 , (NCT06904274)
  • 16 May 2023 Efficacy data from a clinical trial in menorrhagia released by Bayer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top